Seattle Genetics (SGEN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics Reports Third Quarter 2016 Financial Results
October 27, 2016 4:02 PM EDT-Third Quarter 2016 Revenues Were $106.3 Million, Including Record $70.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-Broad Presence at Upcoming American Society of Hematology (ASH) Annual Meeting, Including an Oral Presentation on the ALCANZA Phase 3 Trial and Four Oral Presentations on Vadastuximab Talirine (SGN-CD33A)-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)--... More
